FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 48 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $52,000 | -41.6% | 21,880 | -8.3% | 0.00% | – |
| Q1 2019 | $89,000 | -7.3% | 23,859 | -10.8% | 0.00% | – |
| Q4 2018 | $96,000 | -92.6% | 26,759 | -88.2% | 0.00% | -100.0% |
| Q3 2018 | $1,296,000 | +381.8% | 226,010 | +320.4% | 0.00% | – |
| Q2 2018 | $269,000 | +13.0% | 53,762 | +15.8% | 0.00% | – |
| Q1 2018 | $238,000 | +6.2% | 46,426 | +24.8% | 0.00% | – |
| Q4 2017 | $224,000 | +194.7% | 37,194 | +127.8% | 0.00% | – |
| Q2 2017 | $76,000 | -76.9% | 16,327 | -75.4% | 0.00% | -100.0% |
| Q1 2017 | $329,000 | -31.2% | 66,373 | +54.2% | 0.00% | 0.0% |
| Q4 2016 | $478,000 | +152.9% | 43,046 | +111.4% | 0.00% | – |
| Q3 2016 | $189,000 | -43.2% | 20,358 | -61.1% | 0.00% | -100.0% |
| Q2 2016 | $333,000 | -15.3% | 52,401 | -13.1% | 0.00% | 0.0% |
| Q1 2016 | $393,000 | -10.9% | 60,294 | +10.9% | 0.00% | 0.0% |
| Q4 2015 | $441,000 | +182.7% | 54,388 | +155.5% | 0.00% | – |
| Q3 2015 | $156,000 | -63.8% | 21,285 | -49.4% | 0.00% | -100.0% |
| Q2 2015 | $431,000 | – | 42,039 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |